2025 China Asthma Drugs Market Revenue Opportunities Report
Description
The 2025 China Asthma Drugs Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Asthma Drugs Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the asthma drugs market in China are GlaxoSmithKline (GSK), AstraZeneca, Novartis, and Johnson & Johnson. GSK holds a significant presence with its biological treatment Nucala (mepolizumab), approved as the first anti-IL-5 biologic for severe eosinophilic asthma in China, addressing a major unmet need in severe asthma management. AstraZeneca markets inhaled agents like Symbicort and is advancing late-phase targeted therapies for moderate to severe asthma, including benralizumab and tezepelumab. Novartis offers biologics such as Xolair (omalizumab), widely used in China for asthma treatment. Johnson & Johnson, a major pharma player globally, contributes through its innovative medicines portfolio addressing inflammatory diseases including asthma, though specific asthma drugs in China were less detailed in the sources.
Together, these companies drive China’s growing asthma therapy market, expected to expand significantly due to rising prevalence and unmet clinical needs. GSK leads with advances in long-acting monoclonal antibodies and pipeline acquisitions enhancing respiratory therapies. AstraZeneca and Novartis focus on novel biologics for severe asthma subtypes, improving patient outcomes. The market value in China was around US$2.68 billion in 2022, projected to reach US$4.51 billion by 2030, reflecting strong growth opportunities fueled by these pharmaceutical leaders. Their efforts include development, approvals, and clinical studies aimed at better asthma control and reduced exacerbations in China’s large patient population.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Asthma Drugs Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the asthma drugs market in China are GlaxoSmithKline (GSK), AstraZeneca, Novartis, and Johnson & Johnson. GSK holds a significant presence with its biological treatment Nucala (mepolizumab), approved as the first anti-IL-5 biologic for severe eosinophilic asthma in China, addressing a major unmet need in severe asthma management. AstraZeneca markets inhaled agents like Symbicort and is advancing late-phase targeted therapies for moderate to severe asthma, including benralizumab and tezepelumab. Novartis offers biologics such as Xolair (omalizumab), widely used in China for asthma treatment. Johnson & Johnson, a major pharma player globally, contributes through its innovative medicines portfolio addressing inflammatory diseases including asthma, though specific asthma drugs in China were less detailed in the sources.
Together, these companies drive China’s growing asthma therapy market, expected to expand significantly due to rising prevalence and unmet clinical needs. GSK leads with advances in long-acting monoclonal antibodies and pipeline acquisitions enhancing respiratory therapies. AstraZeneca and Novartis focus on novel biologics for severe asthma subtypes, improving patient outcomes. The market value in China was around US$2.68 billion in 2022, projected to reach US$4.51 billion by 2030, reflecting strong growth opportunities fueled by these pharmaceutical leaders. Their efforts include development, approvals, and clinical studies aimed at better asthma control and reduced exacerbations in China’s large patient population.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
